NVO
Novo’s saying: hold my Wegovy
Novo Nordisk came out swinging with fresh real-world data showing that patients who stayed on semaglutide and escalated to 2 mg had a 6% lower risk of major adverse cardiovascular events than patients who switched to Eli Lilly’s tirzepatide.
That’s not a tiny footnote. In obesity and diabetes land, every little edge is basically a full-blown marketing campaign. Novo is trying to remind the market that semaglutide still has a seat at the head of the GLP-1 table, even as Lilly’s tirzepatide keeps gobbling up attention like the new kid with the coolest sneakers.
And then came the pipeline flex
The company also announced an exclusive licensing deal with Hengrui Pharma for HRS-1596, a phase 1-ready dual GLP-1/GIP agonist. Novo gets global rights outside mainland China, Hong Kong, Macao, and Taiwan, and the deal could reach $2.6 billion with a $300 million upfront payment.
That matters because Novo isn’t just defending its current crown — it’s trying to widen the moat. A once-weekly oral option for obesity and type 2 diabetes would be a pretty big deal if it gets anywhere near the finish line.
Why investors should care
This is the kind of news that can help a stock feel less like it’s just reacting to Lilly and more like it’s building a longer-term metabolic franchise.
- The semaglutide data gives Novo fresh ammo in the GLP-1 battle.
- The Hengrui deal adds another shot on goal in oral metabolic therapy.
- Yes, NVO shares still slipped on the day — because markets love making life complicated.
Big picture: Novo is trying to prove it’s not just in the GLP-1 race. It wants to be the whole track.